Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

mprovement of 0.31 and patients receiving golimumab 100 mg experienced a mean improvement of 0.38 in HAQ score, compared with an improvement of only 0.04 among placebo patients (P < 0.001). At week 24, the improvements were 0.33 and 0.39 in the respective treatment groups, compared with worsening in HAQ score of -0.01 among patients receiving placebo (P < 0.001). HAQ assesses the degree of difficulty a patient has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and other activities of daily living). An improvement in HAQ of at least 0.3 indicates clinically meaningful improvement in physical function.

About the GO-REVEAL Trial

The Golimumab -- A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL) trial involved 405 adults with psoriatic arthritis. Subjects with at least three swollen and tender joints and active psoriatic skin lesions of at least 2 cm in diameter were randomly assigned to receive SC injections of placebo or golimumab (50 or 100 mg) at weeks 0, 4, 8, 12, 16 and 20. At week 16, patients with inadequate arthritis response were switched to golimumab 50 mg (patients originally receiving placebo) or golimumab 100 mg (patients originally receiving golimumab 50 mg). The primary endpoint was ACR 20 response at week 14 for combined golimumab groups and individual golimumab dose groups versus placebo.

Through week 24, the placebo-controlled portion of the study, golimumab was generally well-tolerated, with two percent of golimumab-treated patients experiencing serious adverse events compared with six percent of patients in the placebo group. Injection site reactions occurred in five percent of patients receiving golimumab and three percent of patients receiving placebo. One case of prostate cancer and two cases of basal cell carcinoma were reported in golimumab-treated patients. There were no r
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... Angeles, CA (PRWEB) December 24, 2014 ... wreak havoc on those who have an intolerance to ... to diarrhea, gas, bloating, migraine headaches, joint pain and ... gluten free diet plans that deliver safe and ... certain foods that trigger a gluten allergy reaction. These ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... There’s a lot going on with The ... now in control of the Senate as well as the ... Act. A lawsuit has been brought against President Obama by ... the ACA have resulted in changes to the law without ... will take place to weigh the validity of subsidies provided ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... breathing disorders could face depression, says a study.// ... Wisconsin-Madison studied about 1,400 adults (aged 30-60) for up ... did not have breathing problems during sleep, those with ... times more likely to become depressed during the study, ...
... Anna Pou, during her first ever public appearance, since ... with dangerous injections, confirmed that neither she nor// the ... ,The charge labeled against them by the Louisiana ... second-degree murder. The witness account as mentioned in ...
... has revealed that exposure to high pollution levels can increase ... in Japan have found that the risk of stroke from ... ,Currently breathing and heart problems are associated with the ... hourly levels. ,The findings of the study ...
... (FDA) have approved a virus mix in spray form that ... month.// , ,Processed meats after being packaged get ... combination of viruses that kill this bacteria. Food companies can ... ,This virus mix is not effective against E. ...
... poor training is resulting in unnecessary emergency Caesarean births ... week’s British Medical Journal (BMJ) that expert obstetricians can ... UK, the decision whether to try a vaginal birth, ... Caesarean is taken in the delayed second-stage labor by ...
... A House committee on Wednesday passed a bill that will ... from the South and rural states said that// increased spending ... it is spreading. ,"It shouldn't matter where you ... care and therapy," said Rep. Joe Barton, R-Texas, chairman of ...
Cached Medicine News:Health News:Stroke Linked to High Pollution Levels 2Health News:Skilled Obstetricians to avoid unnecessary Caesareans 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Medicine Products: